Inhibikase Therapeutics (IKT) Stock Highlights

3.2 | +1.27%

2024-12-21 06:23:41

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinsons disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinsons disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Statistics

Range Today

3.07 3.5

Volume Today 1.8M

Range 1 Year

1.12 4.2

Volume 1 Year 52.94M

Range 3 Year

0.79 10.8

Volume 3 Year 85.49M

Range 10 Year

0.79 70.8

Volume 10 Year 101.32M

Highlights

Market Capitalization 189.43M (small)

Floating Shares 1.7M

Current Price 3.2

Price To Earnings -0.88

Price To Revenue 174.84

Price To Book 4.08

Earnings Per Share -3.33

Payout Ratio 0%

Performance

Latest +1.27%

1 Month +59.2%

3 Months +173.5%

6 Months +114.77%

1 Year +130.22%

3 Years -67.28%

5 Years -95%

10 Years -95%

Benchmarks

Market Capitalization

338 / 368

Gross Profits

0 / 278

Total Revenue

261 / 300

Total Rank

156 / 368

Free Cashflow

103 / 352

Performance 5 years

310 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.